Table 1 Participants’ baseline characteristics.
From: Serum biomarkers in people with chronic low back pain and Modic 1 changes: a case-control study
Control (Modic 0) n = 21 | Cases (Modic 1) n = 13 | All patients n = 34 | p-value* | |
|---|---|---|---|---|
Demographic characteristics of patients | ||||
Age (years), mean (95% CI) | 42.0 (37.6; 46.4) | 47.4 (38.9; 56.0) | 44.1 (40.0; 48.1) | 0.23 |
Body mass index (kg/m2), mean (95% CI) | 23.4 (22.3; 24.5) | 26.3 (24.4; 28.3) | 24.5 (23.5; 25.6) | 0.01 |
Currently working (yes), n (%) | 17 (81.0) | 9 (69.2) | 26 (76.5) | 0.43 |
Currently smoking (yes), n (%) | 9 (42.9) | 6 (46.2) | 15 (44.1) | 0.85 |
Characteristics of chronic low back pain | ||||
Low back pain duration (months), mean (95% CI) | 62.7 (41.4; 84.0) | 88.2 (47.9; 128.5) | 72.5 (53.0; 91.9) | 0.24 |
Low back pain intensity (0-100 mm VAS), mean (95% CI) | 45.5 (34.1; 56.8) | 47.6 (35.0; 60.2) | 46.3 (38.2; 54.4) | 0.79 |
Quebec score (0-100), mean (95% CI) | 30.8 (25.0; 36.5) | 37.5 (29.4; 45.5) | 33.3 (28.7; 37.9) | 0.16 |
Worst painful moment in the morning or at night and/or morning stiffness (yes), n (%) | 7 (33.3) | 8 (61.5) | 15 (44.1) | 0.11 |
Current treatments (yes), n (%) | ||||
Painkillers | 14 (66.7) | 5 (38.5) | 19 (55.9) | 0.11 |
Non-steroidal anti-inflammatory drugs | 4 (19.1) | 3 (23.1) | 7 (20.6) | 0.78 |
